Particle.news
Download on the App Store
3 ARTICLES
·
last wk.

Kriya Nets $320 Million Series D as Odyssey Raises $213 Million and Amgen Retools Research Leadership

Private financing signals a move from IPOs to scaling programs backed by mid-stage data, with manufacturing depth a differentiator.

Kriya Therapeutics
Kriya's pipeline is focused on gene therapies that are administered directly to the affected areas for chronic conditions. Credit: metamorworks/Shutterstock.com.

Overview

  • Kriya Therapeutics closed an oversubscribed $320 million Series D co-led by Premji Invest and Patient Square Capital to advance trials and expand its integrated R&D and manufacturing engine.
  • Investors in Kriya’s round included Narya Capital, Peter Thiel and The T1D Fund, and Premji Invest’s Akshay Rai joined the company’s board.
  • Kriya’s pipeline targets locally delivered gene therapies for chronic conditions such as thyroid eye disease, geographic atrophy, trigeminal neuralgia, type 1 diabetes and MASH.
  • Odyssey Therapeutics secured $213 million in Series D financing three months after withdrawing an IPO, adding new backers like Dimension Capital and Jeito Capital as it advances autoimmune programs led by an IBD candidate in mid-stage testing.
  • Amgen hired Genentech veteran Shannon Turley as vice president and co-head of research biology and expanded Saptarsi Haldar’s remit, while recent Phase 2 wins included Dianthus’ GMG data followed by a $251 million stock raise and Merck/Daiichi’s ADC results supporting ongoing regulatory talks.